Do I need a prescription for Malathion 1% cream shampoo?

Malathion 1% cream shampoo is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Malathion 1% cream shampoo?

Malathion 1% cream shampoo is the generic name. It is available under brand names including: Prioderm 1% cream shampoo, Quellada-M 1% cream shampoo. (Source: NHS dm+d — Actual Medicinal Products)

Malathion 1% cream shampoo

Cream

Topical

Malathion is a parasympathomimetic organophosphate compound that is used as an insecticide for the treatment of head lice.

Active ingredients:

Malathion

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC P03AX03

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Malathion

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Malathion

Source: MHRA Products DatabaseOGL 3.0

Updated 6 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Malathion

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Malathion

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

2 branded products available

2 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Malathion on the MHRA register

Prioderm 1% cream shampoo

SSL International Plc

Discontinued

Quellada-M 1% cream shampoo

Haleon UK Trading Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated 4 months ago(1 Mar 2026)

Therapeutically similar medicines

10 similar

Dimeticone 4% gel

Gel

Same therapeutic group

Dimeticone 4% cutaneous spray

Spray

Same therapeutic group

Dimeticone 4% lotion

Other

Same therapeutic group

Benzyl benzoate crystals

Other

Same therapeutic group

Dimeticone 10% cream

Cream

10%

Same therapeutic group

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Loading prescribing data...

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

39718211000001100

dm+d ID

39718211000001100

VTM (Virtual Therapeutic Moiety)

776626002

VMP (Virtual Medicinal Product)

39718211000001100

BNF code (NHS dm+d)

13100400

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

P03AX03

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing the 50 most relevant studies.

Reviews & meta-analyses: 7 · 1999–2026

Sort

A comprehensive systematic review and meta-analysis on the extraction of pesticide by various solid phase-based separation methods: a case study of malathion

Mojtaba Yeganeh, A. Azari, Hamid Reza Sobhi, et al.

International Journal of Environmental Analytical Chemistry, 2021

Systematic review

Cited by 78

A global systematic review of the concentrations of Malathion in water matrices: Meta-analysis, and probabilistic risk assessment.

Y. Vasseghian, E. Drăgoi, Fares Almomani, et al.

Chemosphere, 2021

Systematic review

Cited by 51

Female reproductive toxicity after exposure to malathion or diazinon: a systematic review of rodent and human studies.

Barbosa IG, Lazzari VM, Araújo Leite GA

2025

Systematic review

Diazinon
Malathion
Insecticides

Effects of exposure to malathion on blood glucose concentration: a meta-analysis

M. A. Ramírez-Vargas, E. Flores-Alfaro, M. Urióstegui-Acosta, et al.

Environmental Science and Pollution Research, 2018

Meta-analysis

Cited by 25

Organophosphate toxicity: updates of malathion potential toxic effects in mammals and potential treatments

A. Badr

Environmental Science and Pollution Research, 2020

Review

Cited by 138

Carcinogenicity of tetrachlorvinphos, parathion, malathion, diazinon, and glyphosate.

K. Guyton, D. Loomis, Y. Grosse, et al.

The Lancet. Oncology, 2015

Cited by 792

A comprehensive review on enzymatic degradation of the organophosphate pesticide malathion in the environment

Smita S. Kumar, P. Ghosh, S. K. Malyan, et al.

Journal of Environmental Science and Health, Part C, 2019

Review

Cited by 88

Detection of organophosphorus pesticide – Malathion in environmental samples using peptide and aptamer based nanoprobes

R. Bala, Suman Dhingra, Munish Kumar, et al.

Chemical Engineering Journal, 2017

Cited by 139

Fluorescence and colorimetric dual-mode sensor for visual detection of malathion in cabbage based on carbon quantum dots and gold nanoparticles.

Nini Liang, Xuetao Hu, Wenting Li, et al.

Food chemistry, 2020

Cited by 135

Optimizing the removal of organophosphorus pesticide malathion from water using multi-walled carbon nanotubes

M. Dehghani, Zahra Shariati Niasar, M. Mehrnia, et al.

Chemical Engineering Journal, 2017

Cited by 133

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

None known

Half-life

8-24 hours

Mechanism

Malathion is a nonsystemic, wide-spectrum organophosphate insecticide.

Food interactions

None known

Human targets

2 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

Malathion in an acetone vehicle has been reported to be absorbed through normal human skin only to the extent of 8% of the applied dose.…

Half-life

8-24 hours

8-24 hours

Metabolism

The major metabolites of malathion are the diacid and monoacid metabolites, namely, malathion dicarboxylic acid (DCA) and malathion monocarboxylic acid (MCA).…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Small molecule

About this compound

Malathion is a parasympathomimetic organophosphate compound that is used as an insecticide for the treatment of head lice. Malathion is an irreversible cholinesterase inhibitor and has low human toxicity.

Properties:

liquid

Avg. mass: 330.36 Da

View FDA drug label

DrugBank indication

For patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair.

Also known as(31)

[(dimethoxyphosphinothioyl)thio]butanedioic acid diethyl ester

Carbophos

diethyl (dimethoxyphosphinothioylthio)succinate

Karbofos

Malathion

Maldison

Mercaptothion

O,O-dimethyl S-(1,2-bis(ethoxycarbonyl)ethyl)

Molecular properties(18)

Drug interactions(384)

Known interactions with other medications. Always consult a healthcare professional.

Dipyridamole

Moderate

DB00975

The therapeutic efficacy of Malathion can be decreased when used in combination with Dipyridamole.

Check this interaction

Trazodone

Unknown severity

DB00656

The risk or severity of QTc prolongation can be increased when Trazodone is combined with Malathion.

Check this interaction

Pitolisant

Moderate

DB11642

Malathion may increase the QTc-prolonging activities of Pitolisant.

Check this interaction

Lefamulin

Moderate

DB12825

Lefamulin may increase the QTc-prolonging activities of Malathion.

Check this interaction

Hydroxyzine

Unknown severity

DB00557

The risk or severity of QTc prolongation can be increased when Malathion is combined with Hydroxyzine.

Check this interaction

Ziprasidone

Unknown severity

DB00246

The risk or severity of QTc prolongation can be increased when Malathion is combined with Ziprasidone.

Check this interaction

Haloperidol

Unknown severity

DB00502

The risk or severity of QTc prolongation can be increased when Malathion is combined with Haloperidol.

Check this interaction

Fluoxetine

Unknown severity

DB00472

The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Malathion.

Check this interaction

Abametapir

Unknown severity

DB11932

The serum concentration of Malathion can be increased when it is combined with Abametapir.

Check this interaction

Ponesimod

Unknown severity

DB12016

The risk or severity of bradycardia can be increased when Ponesimod is combined with Malathion.

Check this interaction

Fexinidazole

Unknown severity

DB12265

The risk or severity of adverse effects can be increased when Malathion is combined with Fexinidazole.

Check this interaction

Mobocertinib

Unknown severity

DB16390

The risk or severity of QTc prolongation can be increased when Malathion is combined with Mobocertinib.

Check this interaction

Dabrafenib

Unknown severity

DB08912

The serum concentration of Malathion can be decreased when it is combined with Dabrafenib.

Check this interaction

Telotristat ethyl

Unknown severity

DB12095

The serum concentration of Malathion can be decreased when it is combined with Telotristat ethyl.

Check this interaction

Clozapine

Unknown severity

DB00363

The risk or severity of QTc prolongation can be increased when Malathion is combined with Clozapine.

Check this interaction

Glasdegib

Unknown severity

DB11978

The risk or severity of QTc prolongation can be increased when Malathion is combined with Glasdegib.

Check this interaction

Vilanterol

Unknown severity

DB09082

The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Malathion.

Check this interaction

Oxaliplatin

Unknown severity

DB00526

The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Malathion.

Check this interaction

Quizartinib

Unknown severity

DB12874

The risk or severity of QTc prolongation can be increased when Malathion is combined with Quizartinib.

Check this interaction

Citalopram

Unknown severity

DB00215

The risk or severity of QTc prolongation can be increased when Malathion is combined with Citalopram.

Check this interaction

Pimavanserin

Unknown severity

DB05316

The risk or severity of QTc prolongation can be increased when Malathion is combined with Pimavanserin.

Check this interaction

Gepirone

Unknown severity

DB12184

The risk or severity of QTc prolongation can be increased when Gepirone is combined with Malathion.

Check this interaction

Etrasimod

Unknown severity

DB14766

The risk or severity of QTc prolongation and torsade de pointes can be increased when Etrasimod is combined with Malathion.

Check this interaction

Bedaquiline

Unknown severity

DB08903

The risk or severity of QTc prolongation can be increased when Malathion is combined with Bedaquiline.

Check this interaction

Encorafenib

Unknown severity

DB11718

The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Malathion.

Check this interaction

Givinostat

Unknown severity

DB12645

The risk or severity of QTc prolongation can be increased when Malathion is combined with Givinostat.

Check this interaction

Inotuzumab ozogamicin

Unknown severity

DB05889

The risk or severity of QTc prolongation can be increased when Malathion is combined with Inotuzumab ozogamicin.

Check this interaction

Mavorixafor

Unknown severity

DB05501

The risk or severity of QTc prolongation can be increased when Mavorixafor is combined with Malathion.

Check this interaction

Ribociclib

Unknown severity

DB11730

The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Malathion.

Check this interaction

Revumenib

Unknown severity

DB18515

The risk or severity of QTc prolongation can be increased when Malathion is combined with Revumenib.

Check this interaction

Leuprolide

Unknown severity

DB00007

The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Malathion.

Check this interaction

Goserelin

Unknown severity

DB00014

The risk or severity of QTc prolongation can be increased when Goserelin is combined with Malathion.

Check this interaction

Octreotide

Unknown severity

DB00104

The risk or severity of QTc prolongation can be increased when Octreotide is combined with Malathion.

Check this interaction

Oxytocin

Unknown severity

DB00107

The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Malathion.

Check this interaction

Esmolol

Unknown severity

DB00187

The risk or severity of QTc prolongation can be increased when Esmolol is combined with Malathion.

Check this interaction

Bortezomib

Unknown severity

DB00188

The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Malathion.

Check this interaction

Betaxolol

Unknown severity

DB00195

The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Malathion.

Check this interaction

Fluconazole

Unknown severity

DB00196

The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Malathion.

Check this interaction

Erythromycin

Unknown severity

DB00199

The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Malathion.

Check this interaction

Dofetilide

Unknown severity

DB00204

The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Malathion.

Check this interaction

Azithromycin

Unknown severity

DB00207

The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Malathion.

Check this interaction

Moxifloxacin

Unknown severity

DB00218

The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Malathion.

Check this interaction

Nelfinavir

Unknown severity

DB00220

The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Malathion.

Check this interaction

Pregabalin

Unknown severity

DB00230

The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Malathion.

Check this interaction

Ranolazine

Unknown severity

DB00243

The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Malathion.

Check this interaction

Benzatropine

Unknown severity

DB00245

The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Malathion.

Check this interaction

Anagrelide

Unknown severity

DB00261

The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Malathion.

Check this interaction

Sulfisoxazole

Unknown severity

DB00263

The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Malathion.

Check this interaction

Isradipine

Unknown severity

DB00270

The risk or severity of QTc prolongation can be increased when Isradipine is combined with Malathion.

Check this interaction

Disopyramide

Unknown severity

DB00280

The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Malathion.

Check this interaction

Showing 50 of 384 interactions

Toxicity & overdose

Malathion is slightly toxic via the oral route, with reported oral LD₅₀ values of 1000 mg/kg to greater than 10,000 mg/kg in the rat. It is also slightly toxic via the dermal route, with reported dermal LD₅₀ values of greater than 4000 mg/kg in rats. Moderate poisoning can result in chest tightness, difficulty breathing, bradycardia, tachycardia, tremor/ataxia, blurred vision, and confusion.

Severe, life-threatening signs include coma, seizures, respiratory arrest, and paralysis. Malathion may also be irritating to the skin and eyes.

How it works

Mechanism of action

Malathion is a nonsystemic, wide-spectrum organophosphate insecticide. It inhibits acetylcholinesterase activity of most eukaryotes. Malathion is toxic to aquatic organisms, but has a relatively low toxicity for birds and mammals. The major metabolites of malathion are mono- and di-carboxylic acid derivatives, and malaoxon is a minor metabolite. However, it is malaoxon that is the strongest cholinesterase inhibitor. Cholinesterases catalyze the hydrolysis of the neurotransmitter acetylcholine into choline and acetic acid, a reaction necessary to allow a cholinergic neuron to return to its resting state after activation. Because of its essential function, chemicals that interfere with the action of cholinesterase are potent neurotoxins, causing muscle spasms and ultimately death.

Pharmacodynamics

Malathion is an organophosphate insecticide commonly used to control mosquitos and other flying insects. Pharmaceutically, malathion is used to eliminate head lice. The principal toxicological effect of malathion is cholinesterase inhibition, due primarily to malaoxon and to phosphorus thionate impurities.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Malathion in an acetone vehicle has been reported to be absorbed through normal human skin only to the extent of 8% of the applied dose. Absorption may be increased when malathion is applied to damaged skin. Malathion is rapidly and effectively absorbed by practically all routes including the gastrointestinal tract, skin, mucous membranes, and lungs.

However, it is readily excreted in the urine, and does not accumulate in organs or tissues.

Half-life

8-24 hours

Metabolism

The major metabolites of malathion are the diacid and monoacid metabolites, namely, malathion dicarboxylic acid (DCA) and malathion monocarboxylic acid (MCA). Malaoxon, the active cholinesterase-inhibiting metabolite of malathion, is a minor metabolite. Both malathion and malaoxon are detoxified by carboxyesterases leading to polar, water-soluble compounds that are excreted.

Drug targets(2)

Proteins and enzymes this drug interacts with in the body

Cholinesterase

BE0002180

BCHE

inhibitor

Specific functionacetylcholinesterase activity

Cellular location

Secreted

General function & pharmacology

Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters

Acetylcholinesterase

BE0000426

ACHE

inhibitor

Specific functionacetylcholine binding

Cellular location

Synapse

General function & pharmacology

Hydrolyzes rapidly the acetylcholine neurotransmitter released into the synaptic cleft allowing to terminate the signal transduction at the neuromuscular junction. Role in neuronal apoptosis

Metabolizing enzymes(2)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP1A2Cytochrome P450 1A2

substrate

CYP2B6Cytochrome P450 2B6

substrate

Scientific references(3)

Baker EL Jr, Warren M., Zack M., Dobbin R.D., Miles J.W., Miller S., Alderman L., Teeters W.R.

EPIDEMIC MALATHION POISONING IN PAKISTAN MALARIA WORKERS.

The Lancet

1978311(8054):31-34. doi: 10.1016/s0140-6736(78)90375-6

PMID: 74508 DOI: 10.1016/s0140-6736(78)90375-6

Bonner M.R., Coble J., Blair A., Beane Freeman L.E., Hoppin J.A., Sandler D.P., Alavanja M.C.

Malathion Exposure and the Incidence of Cancer in the Agricultural Health Study.

American Journal of Epidemiology

2007166(9):1023-1034. doi: 10.1093/aje/kwm182

PMID: 17720683 DOI: 10.1093/aje/kwm182

Edwards J.W., Lee S.G., Heath L.M., Pisaniello D.L.

Worker exposure and a risk assessment of Malathion and Fenthion used in the control of Mediterranean fruit fly in South Australia.

Environmental Research

2007103(1):38-45. doi: 10.1016/j.envres.2006.06.001

PMID: 16914134 DOI: 10.1016/j.envres.2006.06.001

ATC classification(1 code)

ATC P03AX03

Affected organisms(1)

Head lice

Experimental properties(4)

External resources(2)

RxList Drugs.com

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Malathion

DB00772

CAS number

121-75-5

UNII (FDA)

U5N7SU872W

InChI Key (molecular fingerprint)

JXSJBGJIGXNWCI-UHFFFAOYSA-N

Additional database identifiers

ChEBI

141474

PubChem Compound

4004

PubChem Substance

46505287

KEGG Compound

C07497

KEGG Drug

D00534

ChemSpider

3864

BindingDB

85372

PharmGKB

PA164748092

Therapeutic Targets Database

DAP000895

Wikipedia

Malathion

ChEMBL

CHEMBL1200468

RxCUI

6606

HUGO Gene Nomenclature Committee (HGNC)

HGNC:983

GenAtlas

BCHE

GeneCards

BCHE

GenBank Gene Database

M32391

GenBank Protein Database

1311630

Guide to Pharmacology

2471

UniProtKB

P06276

UniProt Accession

CHLE_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:108

GenAtlas

ACHE

GeneCards

ACHE

GenBank Gene Database

M55040

GenBank Protein Database

177975

Guide to Pharmacology

2465

UniProtKB

P22303

UniProt Accession

ACES_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2596

GenAtlas

CYP1A2

GeneCards

CYP1A2

GenBank Gene Database

Z00036

Guide to Pharmacology

1319

UniProtKB

P05177

UniProt Accession

CP1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2615

GeneCards

CYP2B6

GenBank Gene Database

M29874

GenBank Protein Database

181296

Guide to Pharmacology

1324

UniProtKB

P20813

UniProt Accession

CP2B6_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 4 months ago(8 Mar 2026)

Structured knowledge from the free knowledge base

Q423005

Wikipedia article

chemical compound

Read on Wikipedia

Research database identifiers

MeSH

D008294

ChEBI

CHEBI:141474

ATC classifications (Wikidata)

P03AX03

Linked open data from Wikidata (Q423005), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.

Source: Q423005CC0 1.0

Updated about 3 hours ago(5 Jul 2026)

Back to medicines

Malathion 1% cream shampoo

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Pharmacy stock checkers

Supply & safety information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Clinical essentials

Pharmacology

Deep science
4

Chemical identifiers

Malathion

Additional database identifiers

DrugBank citations

Wikipedia article

Research database identifiers

Malathion 1% cream shampoo

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Medicines like this

Prescribing statistics

Availability, stocks & shortages

Pharmacy stock checkers

Supply & safety information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

Research & evidence

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Clinical essentials

Pharmacology

Deep science4

Chemical identifiers

Malathion

Additional database identifiers

DrugBank citations

Wikidata linked open data

Wikipedia article

Research database identifiers

Deep science
4